Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively ev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paweł Robak, Janusz Szemraj, Damian Mikulski, Izabela Drozdz, Karolina Juszczak, Dariusz Jarych, Małgorzata Misiewicz, Kacper Kościelny, Wojciech Fendler, Tadeusz Robak
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	bortezomib cMAF MAFb multiple myeloma POMP prognosis Medicine R
Acceso en línea:	https://doaj.org/article/3c8e56eba9894fddbdb44071e012f57c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c8e56eba9894fddbdb44071e012f57c
record_format	dspace
spelling	oai:doaj.org-article:3c8e56eba9894fddbdb44071e012f57c2021-11-11T17:39:28ZPrognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens10.3390/jcm102150282077-0383https://doaj.org/article/3c8e56eba9894fddbdb44071e012f57c2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5028https://doaj.org/toc/2077-0383While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively evaluates the expression of POMP, PSMB5, NRF2, XBP1, cMAF and MAFb proteins in plasma cells isolated from the bone marrow of 39 MM patients treated with bortezomib-based regimens using an enzyme-linked immunosorbent assay (ELISA). The proteins were selected on the basis of previous laboratory and clinical studies in bortezomib-treated MM patients. It was found that the expression of the investigated proteins did not significantly differ between bortezomib-sensitive and bortezomib-refractory patients. However, the expression of some proteins correlated with overall survival (OS); this was significantly shorter in patients with higher POMP expression (HR 2.8, 95% CI: 1.1–7.0, <i>p</i> = 0.0277) and longer in those with higher MAFB expression (HR 0.32, 95% CI: 0.13–0.80, <i>p</i> = 0.0147). Our results indicate that a high expression of POMP and MAFB in MM plasma cells may serve as predictors of OS in MM patients treated with bortezomib-based regimens. However, further studies are needed to determine the role of these factors in effective strategies for improving anti-myeloma therapy.Paweł RobakJanusz SzemrajDamian MikulskiIzabela DrozdzKarolina JuszczakDariusz JarychMałgorzata MisiewiczKacper KościelnyWojciech FendlerTadeusz RobakMDPI AGarticlebortezomibcMAFMAFbmultiple myelomaPOMPprognosisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5028, p 5028 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bortezomib cMAF MAFb multiple myeloma POMP prognosis Medicine R
spellingShingle	bortezomib cMAF MAFb multiple myeloma POMP prognosis Medicine R Paweł Robak Janusz Szemraj Damian Mikulski Izabela Drozdz Karolina Juszczak Dariusz Jarych Małgorzata Misiewicz Kacper Kościelny Wojciech Fendler Tadeusz Robak Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
description	While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively evaluates the expression of POMP, PSMB5, NRF2, XBP1, cMAF and MAFb proteins in plasma cells isolated from the bone marrow of 39 MM patients treated with bortezomib-based regimens using an enzyme-linked immunosorbent assay (ELISA). The proteins were selected on the basis of previous laboratory and clinical studies in bortezomib-treated MM patients. It was found that the expression of the investigated proteins did not significantly differ between bortezomib-sensitive and bortezomib-refractory patients. However, the expression of some proteins correlated with overall survival (OS); this was significantly shorter in patients with higher POMP expression (HR 2.8, 95% CI: 1.1–7.0, <i>p</i> = 0.0277) and longer in those with higher MAFB expression (HR 0.32, 95% CI: 0.13–0.80, <i>p</i> = 0.0147). Our results indicate that a high expression of POMP and MAFB in MM plasma cells may serve as predictors of OS in MM patients treated with bortezomib-based regimens. However, further studies are needed to determine the role of these factors in effective strategies for improving anti-myeloma therapy.
format	article
author	Paweł Robak Janusz Szemraj Damian Mikulski Izabela Drozdz Karolina Juszczak Dariusz Jarych Małgorzata Misiewicz Kacper Kościelny Wojciech Fendler Tadeusz Robak
author_facet	Paweł Robak Janusz Szemraj Damian Mikulski Izabela Drozdz Karolina Juszczak Dariusz Jarych Małgorzata Misiewicz Kacper Kościelny Wojciech Fendler Tadeusz Robak
author_sort	Paweł Robak
title	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
title_short	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
title_full	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
title_fullStr	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
title_full_unstemmed	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
title_sort	prognostic value of resistance proteins in plasma cells from multiple myeloma patients treated with bortezomib-based regimens
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3c8e56eba9894fddbdb44071e012f57c
work_keys_str_mv	AT pawełrobak prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT januszszemraj prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT damianmikulski prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT izabeladrozdz prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT karolinajuszczak prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT dariuszjarych prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT małgorzatamisiewicz prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT kacperkoscielny prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT wojciechfendler prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens AT tadeuszrobak prognosticvalueofresistanceproteinsinplasmacellsfrommultiplemyelomapatientstreatedwithbortezomibbasedregimens
_version_	1718432057520029696

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Ejemplares similares